Division of Endocrinology and Metabolic Diseases, University of Campania "L. Vanvitelli", 80138, Naples, Italy.
Department of Medical and Advanced Surgical Sciences, University of Campania "L. Vanvitelli", Naples, Italy.
J Endocrinol Invest. 2022 Jan;45(1):181-188. doi: 10.1007/s40618-021-01641-1. Epub 2021 Jul 19.
During the COVID-19 pandemic, elective thyroid surgery is experiencing delays. The problem is that the COVID-19 pandemic is ongoing. The research purposes were to systematically collect the literature data on the characteristics of those thyroid operations performed and to assess the safety/risks associated with thyroid surgery during the COVID-19 pandemic.
We used all the procedures consistent with the PRISMA guidelines. A comprehensive literature in MEDLINE (PubMed) and Scopus was made using ''Thyroid'' and "coronavirus" as search terms.
Of a total of 293 articles identified, 9 studies met the inclusion criteria. The total number of patients undergoing thyroid surgery was 2217. The indication for surgery was malignancy in 1347 cases (60.8%). Screening protocols varied depending on hospital protocol and maximum levels of personal protection equipment were adopted. The hospital length of stay was 2-3 days. Total thyroidectomy was chosen for 1557 patients (1557/1868, 83.4%), of which 596 procedures (596/1558, 38.3%) were combined with lymph node dissections. Cross-infections were registered in 14 cases (14/721, 1.9%), of which three (3/721, 0.4%) with severe pulmonary complications of COVID-19. 377 patients (377/1868, 20.2%) had complications after surgery, of which 285 (285/377, 75.6%) hypoparathyroidism and 71 (71/377, 18.8%) recurrent laryngeal nerve injury.
The risk of SARS-CoV-2 transmission after thyroid surgery is relatively low. Our study could promote the restart of planned thyroid surgery due to COVID-19. Future studies are warranted to obtain more solid data about the risk of complications after thyroid surgery during the COVID-19 era.
在 COVID-19 大流行期间,择期甲状腺手术正在推迟。问题在于 COVID-19 大流行仍在持续。本研究的目的是系统地收集有关已行甲状腺手术特点的文献数据,并评估 COVID-19 大流行期间甲状腺手术的安全性/风险。
我们使用了符合 PRISMA 指南的所有程序。在 MEDLINE(PubMed)和 Scopus 中使用“甲状腺”和“冠状病毒”作为搜索词进行了全面的文献检索。
在总共确定的 293 篇文章中,有 9 项研究符合纳入标准。接受甲状腺手术的患者总数为 2217 例。手术指征为恶性肿瘤 1347 例(60.8%)。筛查方案因医院方案而异,并采用了最高级别的个人防护设备。住院时间为 2-3 天。1557 例患者(1557/1868,83.4%)选择行全甲状腺切除术,其中 596 例(596/1558,38.3%)联合淋巴结清扫术。登记了 14 例(14/721,1.9%)交叉感染,其中 3 例(3/721,0.4%)为 COVID-19 严重肺部并发症。术后有 377 例(377/1868,20.2%)患者出现并发症,其中 285 例(285/377,75.6%)为甲状旁腺功能减退症,71 例(71/377,18.8%)为喉返神经损伤。
甲状腺手术后 SARS-CoV-2 传播的风险相对较低。本研究可以促进因 COVID-19 而重新启动计划中的甲状腺手术。未来的研究需要获得更多关于 COVID-19 时代甲状腺手术后并发症风险的更可靠数据。